RAD 2020 Abstracts - Page 1


Abstracts have been published in the British Journal of Dermatology online.
Direct Link to HTML version: https://onlinelibrary.wiley.com/doi/10.1111/bjd.19043
Direct Link to PDF: https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjd.19043

#125 - Safety and Efficacy of Open-Label Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: An Analysis up to 3 Years (LIBERTY AD OLE)

Diamant Thaçi, Mette Deleuran, Robert Bissonnette, Jean-David Bouaziz, Xian Sun, Naimish Patel, Brad Shumel

#126 - DUPILUMAB OFFERS A RAPID IMPROVEMENT IN PRURITUS IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS VS PLACEBO: A POST-HOC ANALYSIS OF A PHASE 3 TRIAL

Eric L. Simpson, Abhijit Gadkari, Lisa A. Beck, H. Chih-ho Hong, Ashish Bansal, Zhen Chen, Paola Mina-Osorio, Randy Prescilla

#127 - Dupilumab Offers Early and Sustained Improvement in Sleep in Adolescents With Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck, Eric L. Simpson, H. Chih-ho Hong, Ashish Bansal, Zhen Chen, Paola Mina-Osorio, Randy Prescilla, Abhijit Gadkari

#128 - Pharmacokinetics, Safety, and Efficacy of Dupilumab in Children Aged ≥ 2 to < 6 Years With Severe, Uncontrolled Atopic Dermatitis (LIBERTY AD PRE-SCHOOL)

Eric L. Simpson, Benjamin Lockshin, Mohamed Kamal, John D. Davis, Xian Sun, Abhijit Gadkari, Ana B. Rossi, Ashish Bansal

#129 - Long-Term Efficacy and Safety of Dupilumab in Adolescents With Atopic Dermatitis: Results From an Open-Label Extension Trial (LIBERTY AD PED-OLE)

Andrew Blauvelt, Emma Guttman-Yassky, Iftikhar Hussain, Zhen Che5, Paola Mina-Osori5, Ana B. Rossi, Ashish Bansal

#130 - Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: Results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5)

Eric Simpson, Seth Forman, Jonathan Silverberg, Matthew Zirwas, Emanual Maverakis, George Han, Emma Guttman-Yassky, Daniel Marnell, Robert Bissonnette, Jill Waibel, Fabio Nunes, Amy DeLozier, Robinette Angle10, Katrin Holzwarth10, Orin Goldblum, Jinglin Zhong, Kim Papp

#132 - Eosinophil Count, Serum CCL17/18/26 and Immunoglobulin E Levels in Atopic Dermatitis: Upadacitinib Phase 2 Study Analysis

Emma Guttman-Yassky, Ana B. Pavel, Jonathan I. Silverberg, Stephan Weidinger, Julie Parmentier, Henrique D. Teixeira, Feng Hong, Lisa A. Beck

#134 - Achieving an itch-free state with upadacitinib: a post-hoc analysis of data from the Phase 2b randomized, double-blind, placebo-controlled trial in moderate-to-severe atopic dermatitis

J Silverberg, K Reich, B Calimlim, Y Gu3, X Hu, H Teixeira, E Guttman-Yassky

#135 - Treatment Withdrawal and Retreatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis from a Phase 2b, Randomized, Controlled Trial

K Reich; D Thaçi; K Papp; J Anderson; X Hu; Y Gu; H Teixeira; E Guttman-Yassky;

#147 - Peak Pruritus Numerical Rating Scale Response With Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Results From a Randomized, Phase 3 Clinical Trial

EL Simpson, S Ständer, G Yosipovitch, B Kim, M Cameron, M DiBonaventura, D Williams, S Tatulych, C Nduaka, H Valdez

© 2020 The Foundation for Dermatology Education.
The Foundation for Dermatology Education is a registered 501(c)(3) nonprofit organization located in Chicago, IL.